New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?

Ann Rheum Dis. 2009 Jun;68(6):767-9. doi: 10.1136/ard.2008.105940.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anti-Inflammatory Agents / economics
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Certolizumab Pegol
  • Cost-Benefit Analysis
  • Humans
  • Immunoglobulin Fab Fragments / economics
  • Immunoglobulin Fab Fragments / therapeutic use
  • Patient Selection
  • Polyethylene Glycols / economics
  • Polyethylene Glycols / therapeutic use
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / economics

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin Fab Fragments
  • Tumor Necrosis Factor-alpha
  • Polyethylene Glycols
  • golimumab
  • Certolizumab Pegol